Net Sales are expected to increase by 25.9 percent Y-o-Y (down 3 percent Q-o-Q) to Rs. 5,020.7 crore, according to Prabhudas Lilladher.
Prabhudas Lilladher has come out with its fourth quarter (January-March’ 19) earnings estimates for the Pharma sector. The brokerage house expects Aurobindo Pharma to report net profit at Rs. 624.9 crore up 18.2% year-on-year (down 15.2% quarter-on-quarter).
Net Sales are expected to increase by 25.9 percent Y-o-Y (down 3 percent Q-o-Q) to Rs. 5,020.7 crore, according to Prabhudas Lilladher.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to rise by 30.2 percent Y-o-Y (down 2.4 percent Q-o-Q) to Rs. 968.2 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
